Summary
Gemcitabine is a new deoxycytidine analog that exhibits significant cytotoxicity against a variety of cultured murine and human tumor cells. The cytotoxic action of gemcitabine appears to be due to the inhibition of DNA synthesis by inhibition of ribonucleotide reductase and by competition with dCTP for incorporation into DNA. We have previously shown that gemcitabine, but not cytosine arabinoside (ara-C), has a broad spectrum of antitumor activity against 7 different types of murine solid tumors. The activity of gemcitabine was schedule dependent. To further characterize its activity, gemcitabine was tested against 12 human carcinoma xenografts. When given on an every 3 day × 4 schedule, the following percent inhibitions (at maximally tolerated doses [MTD]; MTD/2) in tumor growth were seen: MX-1 mammary (93%; 80%), CX-1 colon (92%; 82%), HC-1 colon (96%; 92%), GC3 colon (98%; 94%), VRC5 colon (99%; 100%), LX-1 lung (76%; 61%), CALU-6 lung (75%; 38%), NCI-H460 lung (45%; 46%), HS766T pancreatic (73%; not tested), PaCa-2 pancreatic (69%; 40%), PANC-1 pancreatic (70%; 60%), and BxPC-3 pancreatic (9%; 19%). In contrast, only the LX-1 lung carcinoma xenograft was responsive to ara-C treatment, which inhibited tumor growth by a marginal 62 percent. Thus, like its activity against murine solid tumors, gemcitabine has excellent antitumor activity against a broad spectrum of human solid tumors.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Hertel LW, Kroin JS, Misnr JW, Tustin JM: Synthesis of 2-deoxy-2,2-difluoro-D-ribose and 2-deoxy-2,2-difluoro-D-ribofuranosyl nucleosides. J Org Chem 53:2406–2409, 1988
Keating MJ, McCredie KB, Bodey GP, Smith TL, Gehan E, Freireich EJ: Improved prospects for long-term survival in adults with acute myelogenous leukemia. JAMA 248:2481–2486, 1982
Chabner BA, Meyers CE: Clinical pharmacology of cancer chemotherapy. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology. J.B. Lippincott, Philadelphia, pp 167, 1982
Hertel LW, Boder GB, Kroin JS, Rinzel SM, Poore GA, Todd GC, Grindey GB: Evaluation of the antitumor activity of gemcitabine 2′,2′-difluoro-2′-deoxycytidine. Cancer Res 50:4417–4422, 1990
Braakhuis BJM, van Dongen GAMS, Vermorken JB, Snow GB: Preclinical in vivo activity of 2′,2′-difluorodeoxycytidine (gemcitabine) against human head and neck cancer. Cancer Res 51:211–214, 1991
Boven E, Schipper H, Erkelens CAM: The influence of the schedule and the dose of gemcitabine on the antitumor efficacy in experimental human cancer. Br J Cancer 68:52–56, 1993
Peters GJ, Schornagel JH, Milano GA: Clinical pharmacokinetics of anti-metabolites. Cancer Surv 17:123–156, 1993
Lund B, Kristjansen PEG, Hansen HH: Clinical and preclinical activity of 2′,2′-difluorodeoxycytidine (gemcitabine). Cancer Treat Rev 19:45–55, 1993
Houghton JA, Taylor DM: Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer 37:213–223, 1978
Schultz RM, Merriman RL, Tom JE, Zimmermann JE, Hertel LW, Andis SL, Dudley DE, Rutherford PG, Tanzer LR, Grindey GB: Evaluation of new anticancer agents against the MIA PaCa-2 and PANC-1 human pancreatic carcinoma xenografts. Oncol Res 5:223–228, 1993
Worzalla JF, Bewley JR, Grindey GB: Automated measurement of transplantable solid tumors using digital electronic calipers interfaced to a microcomputer. Invest New Drugs 8:241–251, 1990
Bovin E, Winograd B: The Nude Mouse in Oncology Research. CRC Press, Boca Ratan, Fl, p 135, 1991
Wils JA: Current status of chemotherapy in metastatic pancreatic cancer. Anticancer Res 9:1027–1032, 1989
Chang BK: Differential sensitivity of pancreatic adenocarcinoma cell lines to chemotherapeutic agents in culture. Cancer Treat Rep 57:355–361, 1983
Chang BK, Fredericks W, Rustum YM, Baker RM: Levels of P-glycoprotein in pancreatic cancer cells lines: relation to inherent drug resistance. Proc Am Soc Clin Oncol 7: 115(abstr), 1988
Huang P, Chubb S, Hertel LW et al.: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6100–6117, 1991
Heinemann V, Xu Y-Z, Chubb S et al.: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′-difluorodeoxycytidine. Mol Pharmacol 38:567–572, 1990
Heinemann V, Hertel LW, Grindey GB, Plunkett W: Comparison of the cellular pharmacokinetics and toxicity of 2′,2′-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031, 1988
Plunkett W, Grindey GB: Pharmacokinetics of the 5′-triphosphates of arabinosylcytosine and 2′,2′-difluorodeoxycytidine in L1210 cells. Nucleic Acids Symp Ser 18:77–79, 1987
Fujita M, Fujita F, Inaba H, Taguchi T: Antitumor activity of LY188011, a new deoxydytidine analog, against human cancers xenografted into nude mice. Jpn J Cancer Chemother 21:517–523, 1994
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Merriman, R.L., Hertel, L.W., Schultz, R.M. et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung and pancreatic xenograft models. Invest New Drugs 14, 243–247 (1996). https://doi.org/10.1007/BF00194526
Issue Date:
DOI: https://doi.org/10.1007/BF00194526